Clinical trials: Non-metastatic Pancreas Cancer
Non-small Cell Lung Cancer, Esophageal Cancer
Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers
Patients with resectable solid primary cancers and even limited number of metastases are potentially curable. However, most patients develop recurrences despite surgery.
- Conditions
- Non-small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer
- Trial name
- NCT02838836
- Testing
- Study sample collection
- Where
- United States
- Volunteers
- 620 people, healthy volunteers welcome
- Sponsor
- University of Missouri-Columbia
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
This clinical trial is studying the amount of EF5 and motexafin lutetium present in tumor cells and/or normal tissues of patients with abdominal (such as ovarian, colon, or stomach cancer) or non-small cell lung cancer.
- Conditions
- Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Fallopian Tube Cancer, Gastrointestinal Stromal Tumor
- Trial name
- NCT00087191
- Testing
- EF5, motexafin lutetium, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of escalating doses of RMC-6291 (KRAS G12C(ON) inhibitor) monotherapy in adult subjects with advanced solid tumors and to identify the…
- Conditions
- Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor
- Trial name
- NCT05462717
- Testing
- RMC-6291
- Where
- 64 sites in United States, Australia and 11 more
- Volunteers
- 222 people
- Sponsor
- Revolution Medicines, Inc.
KRAS Altered Advanced or Metastatic Solid Tumors
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AMG 410 when administered alone or in combination with other agents in…
- Trial name
- NCT07094113
- Testing
- AMG 410, Pembrolizumab, Panitumumab
- Where
- 39 sites in United States, Australia and 12 more
- Volunteers
- 434 people
- Sponsor
- Amgen
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
This phase Ib trial determines if samples from a patient's cancer can be tested to find combinations of drugs that provide clinical benefit for the kind of cancer the patient has.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia, Ann Arbor Stage III Hodgkin Lymphoma
- Trial name
- NCT03878524
- Testing
- Abemaciclib, Abiraterone, Afatinib
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- OHSU Knight Cancer Institute
Pancreatic Adenocarcinoma Metastatic, Lung Cancer (NSCLC)
XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.
This is a global, multi-center, open-label, Phase I/II first-in-human study of XNW27011 monotherapy as an investigational product (IP) in patients with locally advanced and/or metastatic solid tumors who have failed or are…
- Conditions
- Pancreatic Adenocarcinoma Metastatic, Lung Cancer (NSCLC), Ovarian Cancer, Colorectal Cancer Metastatic
- Trial name
- NCT06792435
- Testing
- XNW27011
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Pancreatic Cancer
A Trial of Chemo & Radiation Therapy for Pancreatic Cancer
This is an open-label, non-randomized, combination study of cetuximab, gemcitabine, 5-FU, and external beam radiotherapy in patients with locally advanced, non-metastatic pancreatic cancer.
- Trial name
- NCT00424827
- Testing
- Gemcitabine/Fluorouracil with External Beam Radiation
- Volunteers
- 11 people
- Sponsor
- University of Massachusetts, Worcester
Metastatic Solid Tumor, Recurrent Solid Tumor
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer.
- Conditions
- Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
- Trial name
- NEXUS-01 (NCT06465069)
- Testing
- LY4052031, Pembrolizumab
- Where
- 39 sites in United States, Australia and 6 more
- Volunteers
- 460 people
- Sponsor
- Eli Lilly and Company
Gastrinoma, Glucagonoma
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
RATIONALE: Everolimus and vatalanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor
- Trial name
- NCT00655655
- Testing
- everolimus, vatalanib, pharmacological study
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- Mayo Clinic
Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
- Trial name
- NCT05379985
- Testing
- RMC-6236
- Where
- 21 sites in United States
- Volunteers
- 754 people
- Sponsor
- Revolution Medicines, Inc.
Bladder Cancer, Breast Cancer
Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Kidney Cancer
- Trial name
- NCT00004095
- Testing
- gemcitabine hydrochloride, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Northwestern University
Metastatic, Melanoma
Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers
The main purpose of this study is to determine how best to combine hypofractionated radiotherapy, MEDI4736, and tremelimumab and to determine how safe and tolerable hypofractionated radiotherapy, MEDI4736, and tremelimumab are…
- Conditions
- Metastatic, Melanoma, Non Small Cell Lung Cancer (NSCLC), Breast Cancer
- Trial name
- NCT02639026
- Testing
- Radiotherapy, MEDI4736, Tremelimumab
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Solid Tumor, Adult, Colorectal Cancer
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer…
- Conditions
- Solid Tumor, Adult, Colorectal Cancer, NSCLC, Non Small Cell Lung Cancer
- Trial name
- EVEREST-2 (NCT06051695)
- Testing
- A2B694, A2B543, xT CDx with HLA-LOH Assay
- Where
- 12 sites in United States
- Volunteers
- 474 people
- Sponsor
- A2 Biotherapeutics Inc.
HER2-positive Breast Cancer, HER2 Gene Mutation
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies.
- Conditions
- HER2-positive Breast Cancer, HER2 Gene Mutation, HER-2 Gene Amplification, HER2 Positive Gastric Cancer
- Trial name
- NCT03602079
- Testing
- A166
- Where
- 10 sites in United States
- Volunteers
- 49 people
- Sponsor
- Klus Pharma Inc.
Pancreatic Cancer
A Study of Volociximab in Combination With Gemcitabine in Metastatic Pancreatic Cancer
This clinical trial is being conducted to determine tumor response and preliminary safety of a monoclonal antibody that specifically binds to a cell surface receptor (α5β1 integrin) that is required for the establishment of new…
- Trial name
- NCT00401570
- Testing
- Volociximab, Gemcitabine
- Where
- 6 sites in United States, United Kingdom
- Volunteers
- 40 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Metastatic Pancreatic Cancer
Phase 2 Study of S-1 as 2nd Line Therapy in Metastatic Pancreatic Cancer
The purpose of this study is to determine whether S-1 is effective as 2nd line therapy in slowing tumor activity in patients with metastatic pancreatic cancer who have previously received 1st line treatment with a gemcitabine…
- Trial name
- NCT00652054
- Testing
- S-1
- Volunteers
- 39 people
- Sponsor
- Taiho Oncology, Inc.
Breast Neoplasms, Pancreatic Neoplasms
Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer
The purpose of this study is to assess safety of nab-paclitaxel based chemotherapy regimens administered prior to and/or in combination with nivolumab in Pancreatic Cancer, Non Small Cell Lung Cancer (NSCLC) and Metastatic Breast…
- Trial name
- NCT02309177
- Testing
- nab-Paclitaxel, Nivolumab, Gemcitabine
- Where
- 15 sites in United States
- Volunteers
- 114 people
- Sponsor
- Celgene
Pancreatic Cancer
Gemcitabine, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- SCALOP (NCT01032057)
- Testing
- capecitabine, gemcitabine hydrochloride, quality-of-life assessment
- Where
- 26 sites in United Kingdom
- Volunteers
- 114 people
- Sponsor
- Lisette Nixon
Colorectal Cancer, Locally Advanced
QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors
This is a multi-center, 2-part phase 1b/2 study of AMG 655 in combination with AMG 479 to be conducted in the United States and Spain.
- Conditions
- Colorectal Cancer, Locally Advanced, Metastatic Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT00819169
- Testing
- AMG 479, AMG 655
- Volunteers
- 89 people
- Sponsor
- NantCell, Inc.
Non-small Cell Lung Cancer, Colorectal Carcinoma
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
Phase I Study, a master protocol to investigate TCR-Engineered T cells recognizing KRAS mutations in adult subjects with Unresectable, Advanced, and/or Metastatic Solid Tumors.
- Conditions
- Non-small Cell Lung Cancer, Colorectal Carcinoma, Pancreatic Ductal Adenocarcinoma, Endometrial Cancer
- Trial name
- NCT06218914
- Testing
- NT-112: Autologous, engineered T Cells targeting KRAS G12D, AZD0240: Autologous, engineered T Cells targeting KRAS G12D
- Where
- 18 sites in United States
- Volunteers
- 108 people
- Sponsor
- AstraZeneca